{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(7)"],"submitter":["Wolach O"],"pubmed_abstract":["<h4>Abstract</h4>Venetoclax plus hypomethylating agents are considered standard of care for patients with acute myeloid leukemia (AML) judged ineligible for intensive chemotherapy (IC). Real-world studies complement clinical trials, because patterns of patient selection, treatment exposure, and postremission management may vary. This prospective observational multicenter study included 209 newly diagnosed IC-ineligible patients with a median age 75 years (interquartile range, 71-81 years). A high proportion of patients had secondary AML (53.7%), adverse-risk disease (35.3%), and complex karyotype (15.5%). At a median follow-up of 22.5 months (range, 0.1-43), median overall survival (mOS) was 11.7 months (95% confidence interval [CI], 9.9,15.4). Composite complete remission was achieved in "],"journal":["Blood advances"],"pagination":["1544-1554"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11986219"],"repository":["biostudies-literature"],"pubmed_title":["Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study."],"pmcid":["PMC11986219"],"pubmed_authors":["Stemer G","Levi I","Cohen R","Berelovich J","Frankel N","Nachmias B","Hellmann I","Moshe Y","Zuckerman T","Okasha D","Wolach O","Canaani J","Berger AJ","Ofran Y","Bleterman A","Amitai I","Dally N","Tadmor T","Tavor S","Ganzel C","Grunspan M","Barak M"],"additional_accession":[]},"is_claimable":false,"name":"Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.","description":"<h4>Abstract</h4>Venetoclax plus hypomethylating agents are considered standard of care for patients with acute myeloid leukemia (AML) judged ineligible for intensive chemotherapy (IC). Real-world studies complement clinical trials, because patterns of patient selection, treatment exposure, and postremission management may vary. This prospective observational multicenter study included 209 newly diagnosed IC-ineligible patients with a median age 75 years (interquartile range, 71-81 years). A high proportion of patients had secondary AML (53.7%), adverse-risk disease (35.3%), and complex karyotype (15.5%). At a median follow-up of 22.5 months (range, 0.1-43), median overall survival (mOS) was 11.7 months (95% confidence interval [CI], 9.9,15.4). Composite complete remission was achieved in ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T13:09:51.405Z","creation":"2025-07-12T03:04:08.772Z"},"accession":"S-EPMC11986219","cross_references":{"pubmed":["39637307"],"doi":["10.1182/bloodadvances.2024014014"]}}